Who is the current CEO of Moderna, Inc.?

Moderna, Inc. is a public company listed on NASDAQ under ticker MRNA. Moderna makes money from product sales of mRNA vaccines and from collaboration, grant, and licensing revenue tied to its mRNA platform and pipeline.

Moderna makes money from product sales of mRNA vaccines and from collaboration, grant, and licensing revenue tied to its mRNA platform and pipeline.

Stéphane Bancel

Chief Executive Officer

Legacy

Bancel has led Moderna from a pre-revenue startup to a $180 billion market cap at its peak, overseeing the development of Spikevax in record time and the company's transition to a multi-product biotechnology enterprise. He has managed the $2.2 billion cost-reduction program in 2025 and set the target of cash break-even by 2028. The leader's tenure has shaped Moderna's organizational culture, strategic priorities, and financial performance during a critical period of transition.

Noubar Afeyan

Chairman of the Board

Legacy

Afeyan has provided strategic vision and capital access through Flagship Pioneering, guiding Moderna's financing strategy and platform-focused business model. He has been instrumental in the company's IPO and subsequent capital raises. The leader's tenure has shaped Moderna's organizational culture, strategic priorities, and financial performance during a critical period of transition.

Stephen Hoge

President

Legacy

Hoge has overseen Moderna's clinical development and regulatory strategy, leading the COVID vaccine program from preclinical to approval and managing the pipeline diversification into oncology and rare diseases. The leader's tenure has shaped Moderna's organizational culture, strategic priorities, and financial performance during a critical period of transition.

Jamey Mack

Chief Financial Officer

Legacy

Mack has managed Moderna's financial transition from pandemic profitability to endemic losses, overseeing the $2.2 billion cost-reduction program and capital allocation strategy during the cash burn period. The leader's tenure has shaped Moderna's organizational culture, strategic priorities, and financial performance during a critical period of transition.

Jacqueline Miller

Chief Medical Officer

Legacy

Miller joined as CMO in 2024 and departed in 2025 after leading the clinical strategy for the company's pipeline programs during a critical transition period. The leader's tenure has shaped Moderna's organizational culture, strategic priorities, and financial performance during a critical period of transition.

Challenges & Strategic Context

The biggest risk is that post-pandemic vaccine revenue keeps shrinking before newer respiratory, oncology, and rare-disease products become large enough to offset losses.

Related Companies

Gilead Sciences, Inc.

Compare Moderna, Inc. With Competitors

Moderna, Inc. vs Gilead Sciences, Inc.

Explore Moderna

Core profile pages, annual revenue records, and related research hubs for this company.

Company Overview

Moderna makes money from product sales of mRNA vaccines and from collaboration, grant, and licensing revenue tied to its mRNA platform and pipeline.